USC Norris Cancer Center
Welcome,         Profile    Billing    Logout  
 38 Trials 
55 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wong, Michael
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Not yet recruiting
3
9320
RoW
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD
Novavax
COVID-19
02/25
02/26
NCT06281678: A Study of IBI363 in Subjects with Advanced Solid Malignancies

Recruiting
2
178
US
IBI363
Innovent Biologics (Suzhou) Co. Ltd.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
03/26
12/26
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
NCT06680128: A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Not yet recruiting
1/2
402
RoW
GBP560-A, GBP560-B, IXIARO, IMOJEV, Normal Saline (Placebo)
SK Bioscience Co., Ltd.
Japanese Encephalitis Virus Disease
06/26
03/28
NCT05620940: A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

Recruiting
1
40
RoW
Vivitrol Injectable Product, IVL3004, IVL4002
Inventage Lab., Inc.
Opioid Dependence, Alcohol Dependence
05/25
05/25
NCT05831995: Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

Terminated
1
12
US
ABM-168
ABM Therapeutics Corporation
Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
06/24
06/24
Contact, Use Central
NCT03684018 / 2018-003430-33: Two Dose Levels of Privigen in Pediatric CIDP

Recruiting
4
30
US
IgPro10, Privigen
CSL Behring
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/29
12/29
PAT-CHINA-303, NCT05136664: Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

Recruiting
3
200
RoW
Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B)
Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd
Hyperkalemia, Renal Insufficiency, Chronic
12/25
03/26
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Active, not recruiting
3
136
US
Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo
CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
Graft Versus Host Disease (GVHD)
06/24
12/24
RECLAIIM, NCT04044690 / 2018-003171-35: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Active, not recruiting
3
126
Europe, Japan, US, RoW
human immunoglobulin G, IgPro20, Hizentra, Placebo
CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406
Dermatomyositis
05/28
05/28
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Recruiting
3
177
Canada, US
IgPro20, HIZENTRA®, Placebo
CSL Behring
Post-COVID Postural Orthostatic Tachycardia Syndrome
09/27
09/27
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Active, not recruiting
3
20
Europe, Canada, US, RoW
CSL312, Garadacimab
CSL Behring
Hereditary Angioedema (HAE)
11/26
11/26
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Recruiting
3
35
Canada, US, RoW
CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec
CSL Behring
Hemophilia B
10/28
10/28
MODULAATE, NCT03805789 / 2018-000329-29: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Recruiting
2/3
310
Europe, Japan, US, RoW
Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor, Placebo
CSL Behring, Commercial/Industry, CSL
Acute-graft-versus-host Disease
09/25
03/27
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Recruiting
2/3
2310
Europe, Canada, Japan, US, RoW
CSL300, Clazakizumab, Placebo
CSL Behring
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease
12/28
12/28
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Active, not recruiting
2
81
Europe, RoW
Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL
Astellas Pharma Europe Ltd.
Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation
10/15
12/25
KOR-PED-202, NCT06593392: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Not yet recruiting
2
18
Europe
Difelikefalin
Vifor Fresenius Medical Care Renal Pharma
Pruritus, Chronic Kidney Diseases
08/29
08/29
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Recruiting
2
38
US
TARA-002
Protara Therapeutics
Lymphatic Malformation
12/25
05/26
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

Recruiting
2
127
Canada, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
05/30
08/30
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Terminated
1
52
Europe
CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo
CSL Behring
Immune Complex-mediated Autoimmune Diseases
03/23
03/23
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge

Completed
1
40
Europe
CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo
CSL Behring
Healthy Volunteers
07/23
07/23
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

Completed
1
78
Europe
Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo
CSL Behring
Asthma
11/23
11/23
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Completed
1
10
US
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
09/24
09/24
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Completed
1
12
Europe, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
09/24
10/24
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Recruiting
1
60
RoW
CSL040, Placebo
CSL Behring
Disease Driven by Complement Activation
04/25
04/25
THRIVE-1, NCT05011370: Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

Completed
N/A
80
Europe, US
Protara Therapeutics
Intestinal Failure-associated Liver Disease
06/23
06/23
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

Recruiting
N/A
500
US
HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX)
CSL Behring
Hemophilia B
08/43
08/43
Pullarkat, Vinod
NCT04747613: Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Recruiting
3
250
Europe, Japan, US, RoW
Iptacopan, LNP023
Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
10/27
10/27
NCT04284228: Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT

Active, not recruiting
1/2
22
US
Infusion of NEXI-001 T Cells
NexImmune Inc.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
10/24
03/25
NCT04810611: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Terminated
1
33
Europe, US, RoW
MBG453, sabatolimab, NIS793, canakinumab, ACZ885
Novartis Pharmaceuticals
Myelodysplastic Syndromes
04/24
04/24
NCT04937166: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies

Recruiting
1
36
US
DSP107, Azacitidine, Vidaza, Venetoclax, Venclexta, Venclyxto
Kahr Medical
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
06/25
06/25
Lu, Janice
DARE, NCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Recruiting
2
70
US
Palbociclib, IBRANCE, Fulvestrant, Faslodex, Adjuvant Therapy, Standard of Care
Criterium, Inc.
Breast Cancer
12/27
12/27
Kummar, Shivaani
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
NCT04260256: A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

Recruiting
2
40
US
[18F]F-AraG, VisAcT
CellSight Technologies, Inc., Stanford University, Oregon Health and Science University
Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit
11/26
11/26
EDO-S101-1002, NCT03345485 / 2020-004246-11: Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

Completed
1/2
71
Europe, Canada, US
Tinostamustine 60mg/m2 over 30min, EDO-S101, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, EDO-S101., Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Mundipharma Research Limited, Mundipharma Research Limited
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
07/22
03/23
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
NCT06320405: Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Recruiting
1/2
38
US
Axatilimab, Anti-M-CSFR Monoclonal Antibody SNDX-6352, SNDX 6352, SNDX-6352, SNDX6352, UCB6352, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz
OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
04/27
04/29
GV20-0251-100, NCT05669430: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Solid Tumor Malignancies

Recruiting
1/2
365
US
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], MK-3475
GV20 Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
12/26
09/27
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
NCT04601402: GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Completed
1
11
US
GEN-001, Avelumab, Bavencio
Genome & Company, Merck KGaA, Darmstadt, Germany, Pfizer
Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
01/23
01/23
TEAD-AST-101, NCT06251310: SW-682 in Advanced Solid Tumors

Recruiting
1
186
US
SW-682, Combination Therapy
SpringWorks Therapeutics, Inc.
Advanced Solid Tumor, Mesothelioma, Malignant
01/30
06/30
NCT05601219: A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Terminated
1
46
US
ADA-011, PD(L)-1 inhibitor
Adanate, Inc
Solid Tumor, Adult
10/24
10/24
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
Chamberlain, Marc
NCT04691375: A Study of PY314 in Subjects With Advanced Solid Tumors

Terminated
1
86
US
PY314, Combination Therapy: PY314 + Pembrolizumab, Pembrolizumab
Ikena Oncology, Gilead Sciences
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
08/23
09/23
NCT04682431: A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Terminated
1
127
US
PY159 Single agent dose level 1, PY159, PY159 Single agent dose level 2, PY159 Single agent dose level 3, PY159 Single agent dose level 4, PY159 Single agent dose level 5, PY159 Single agent dose level 6, PY159 Single agent dose level 7, PY159/Pembrolizumab Combination dose level 1, Pembrolizumab, PY159/Pembrolizumab Combination dose level 2, PY159/Pembrolizumab Combination dose level 3, PY159/Pembrolizumab Combination dose level 4, PY159 Single agent dose expansion cohort, PY159/Pembrolizumab Combination dose expansion cohort 1, PY159/Pembrolizumab Combination dose expansion cohort 2, PY159/Pembrolizumab Combination dose expansion cohort 3, PY159/Pembrolizumab Combination dose expansion cohort 4, PY159/Pembrolizumab Combination dose expansion cohort 5, PY159/Pembrolizumab Combination dose expansion cohort 6
Ikena Oncology, Gilead Sciences
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Cancer, Head and Neck Cancer
08/23
08/23
Kaiser, Andreas M
NCT03818724: Treatment Success With the CoolLoop Cryoablation System

Recruiting
N/A
540
Europe
CoolLoop® cryoablation system
afreeze GmbH, Raffeiner GmbH
Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Arrhythmias, Cardiac, Cardiovascular Diseases, Heart Diseases
01/25
01/25
Massopust, Kristy
KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Active, not recruiting
1/2
115
Europe, Canada, US
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab
Nouscom SRL, Merck Sharp & Dohme LLC
Solid Tumor, Adult
04/25
11/26
Xia, Bing
TQB2450-III-05, NCT04325763: A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Recruiting
3
315
RoW
TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Stage III Non-small-cell Lung Cancer
12/22
03/25
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

Recruiting
1
316
RoW
HSK42360
Haisco Pharmaceutical Group Co., Ltd.
Solid Tumors
08/26
07/27
Harton, Lisa
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
Trey, Hannah
APPELHUS, NCT04889430 / 2020-005186-13: Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Recruiting
3
50
Europe, Japan, US, RoW
Iptacopan, LNP023
Novartis Pharmaceuticals, Novartis Pharma AG
Atypical Hemolytic Uremic Syndrome
09/28
03/29
Ong, Song
APPELHUS, NCT04889430 / 2020-005186-13: Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Recruiting
3
50
Europe, Japan, US, RoW
Iptacopan, LNP023
Novartis Pharmaceuticals, Novartis Pharma AG
Atypical Hemolytic Uremic Syndrome
09/28
03/29

Download Options